Clinical Trials
Parkinson's Foundation Launches Registry for Rare Subtypes
The Parkinson's Foundation opened enrollment for a global registry tracking people with rarer Parkinson's subtypes, including LRRK2 genetic mutations and early-onset cases. The registry aims to accelerate research by connecting researchers with the specific patient populations needed for targeted drug trials. Participation is free and fully remote. *
parkinson.orgTelehealth Visits Reduce Barriers to Trial Participation
A new analysis of 3,000 Parkinson's patients found that those offered telehealth options were 40% more likely to enroll in clinical trials. Remote assessments for motor function and quality of life were found to be equally reliable as in-person visits for most trial endpoints. Researchers hope this will diversify trial populations beyond major urban centers. *
npjparkinsonism.comDeep Brain Stimulation Device Approved for Broader Use
The FDA expanded approval of a market-leading deep brain stimulation (DBS) system to include people over 70 with medication-resistant tremor. The device, which delivers electrical stimulation to specific brain regions, had previously been limited to younger patients. Real-world data showed it reduces tremor severity by 60-80% in appropriately selected candidates. *
fda.gov
Breakthrough Treatments
Phase 3 Trial of Neuroprotective Drug Reports Positive Results
A large Phase 3 trial of an investigational neuroprotective compound showed statistically significant slowing of motor progression in people with early-stage Parkinson's. The drug, which targets mitochondrial dysfunction in dopamine neurons, could become the first disease-modifying therapy approved for broad use if results hold up through regulatory review. *
thelancet.comNew Formulation of Carbidopa-Levodopa Shows Better Absorption
A novel intestinal gel formulation of carbidopa-levodopa achieved more stable blood levels than standard oral medications in a 6-month trial. Patients reported fewer sudden "off" periods and improved "on" time without troublesome dyskinesia. The treatment involves a small pump worn externally, similar to insulin pumps used in diabetes. *
abdominal.orgImmunotherapy Approach Clears Early Safety Review
An experimental antibody therapy designed to flag alpha-synuclein for immune destruction passed its Phase 1 safety review with no serious adverse events. The therapy trains the immune system to recognize and clear toxic protein aggregates. A Phase 2 trial testing whether it slows progression is now being planned. *
biotech.com
Lifestyle Interventions
Vigorous Exercise Three Times Weekly Shows Strongest Benefits
A meta-analysis of 28 exercise studies in Parkinson's found that moderate-to-vigorous aerobic exercise performed at least 3 times per week produced the largest improvements in walking speed, balance, and quality of life. Researchers recommend activities like cycling, swimming, or brisk walking that elevate heart rate consistently. *
pmajournal.orgMediterranean Diet Linked to Slower Cognitive Decline
A longitudinal study of 500 people with Parkinson's found that those following a Mediterranean-style diet — rich in vegetables, fish, and olive oil — showed slower cognitive decline over 3 years compared to those eating a typical Western diet. The association was independent of physical activity levels, suggesting diet itself plays a role. *
nutritional.neurology.comBoxing Training Programs Spread to Rural Communities
Non-contact boxing programs designed specifically for Parkinson's have expanded to over 200 community gyms in the US, up from fewer than 50 five years ago. Participants report improvements in strength, balance, and mood. The social community aspect is cited as a major driver of long-term adherence. *
parkinson.org
Emerging Research
Novel Target for Preventing Neuron Death Identified
Researchers identified a previously unknown mechanism by which Parkinson's neurons die, involving a specific calcium channel. Blocking this channel in animal models prevented neuron loss and reversed motor symptoms. This pathway had not been targeted by any existing Parkinson's drug, offering a fresh therapeutic angle. *
pnas.orgSmartphone App Detects Swallowing Difficulties Early
An AI-powered smartphone app accurately detected swallowing difficulties (dysphagia) in 87% of cases using voice and breathing patterns recorded during regular phone calls. Early detection allows dietary modifications and speech therapy before serious complications like aspiration pneumonia develop — a leading cause of death in advanced Parkinson's. *
Protein Biomarker Panel Predicts Treatment Response
Scientists developed a blood test combining four protein biomarkers that predicts whether a person will respond well to a specific Parkinson's medication with 78% accuracy. This could help neurologists personalize treatment choices rather than relying on trial-and-error prescribing, reducing months of ineffective medication trials. *
n.neurology.org
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.